Allergy Therapeutics surprised by the results of PQ Birch jab trial

03:26 EDT 18 Mar 2019 | Proactive Investors

The B301 trial was a multi-centre, double-blind, placebo-controlled study designed to test the efficacy in birch-pollen induced seasonal allergic rhinitis.

Original Article: Allergy Therapeutics surprised by the results of PQ Birch jab trial

More From BioPortfolio on "Allergy Therapeutics surprised by the results of PQ Birch jab trial"